to spread more easily. that s number one. number two is the existing vaccines are still really protective against severe disease, but we have been talking about the waning immunity overall with these new variants and subvariants. that s what s really driving the thinking. there was a lots of enthusiasm. we ll see what the fda says, but it s pretty clear some sort of booster that is specific to an omicron subvariant is probably what s going to be recommended by the fda. the challenge, jake, is this. let me show you what has happened with omicron just over the past couple weeks here in the united states. we knew, you know, the original omicron subvariants were very powerful and spread very quickly. between june 12th and june 18th, the subvariants had a 37.4%, that was the percentage of cases. now it s over half. that happened just within a week. so that gives you an idea of how much of a moving target this is. lots of enthusiasm for an omicron specific booster. but these numbers will cha